25.08.2014 • News

Germany Gives Green Light for Dea Takeover by Russians

Germany's economics ministry has given the go-ahead for energy group RWE to sell its oil and gas unit DEA to a group of investors led by Russian tycoon Mikhail Fridman.

A clause in Germany's foreign trade law, would have allowed the ministry to stop the deal, announced earlier this year, if there were concrete signs it threatened "public safety and order," but the clause has never been invoked.

In a statement, the ministry said it did not expect the deal to negatively impact Germany's energy supply.

When it was first announced the €5.1 billion sale was criticized by senior German politicians in March, as relations between Russia and the West deteriorated over Ukraine.

The sale will hand Fridman, Russia's second-richest man, and other co-investors stakes in about 190 oil and gas licenses or concessions in Europe, the Middle East and North Africa.

Germany currently receives more than a third of its gas and oil from Russia. More than 6,000 German companies are active in the country and business associations and trade bodies have warned that an escalation in tensions over Ukraine would result in catastrophic losses for firms.

RWE also must obtain approval from other countries in which Dea has activities, including the UK, Norway, Denmark and Egypt. Germany's approval was regarded as the biggest challenge, however,

The European Commission signalled its approval in July.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read